Urology Fellowship & Educational Programs: Treatment & Research Achievements

Over the past 50 years Memorial Sloan Kettering has made many important contributions to urologic oncology. Listed below are some of the most significant and enduring scientific contributions from urologists, medical oncologists, radiation therapists, pathologists, and other physicians and scientists at MSKCC. Many of the published papers that documented these contributions were co-authored by fellows and residents.

Bladder Cancer

Year Contributions in Treatment and Research
1943-1949 Techniques of Radical Cystectomy and Pelvic Lymphadenectomy
1952 Dr. Myron Melamed Describes Carcinoma-In-Situ of the Urothelium
1956 Technique of Urethrectomy
1959 Preoperative Irradiation and Radical Cystectomy
1973 Technique of In-Continuity Urethrectomy during Radical Cystectomy
1974 Outpatient Cystoscopy and Fulguration of Recurrent Superficial Papillary Bladder Tumors
1975 Identification and Characterization of Tumor-Associated Antigens
1979 Diagnostic Value of Urinary Cytology and Flow Cytometry
1979-1984 Intravesical Bacillus Calmette-Guerin (BCG) for Superficial Bladder Tumors and Randomized Trials of BCG, used for FDA Approval
1981 Ureteroscopic Destruction of Upper Tract Tumors
1983 Neoadjuvant M-VAC Chemotherapy and Radical Cystectomy
1983-1992 M-VAC Chemotherapy Cures Transitional Cell Carcinoma
1983-1995 Bladder-Sparing Strategies for Invasive Bladder Cancer
1989 Prognostic Significance of Lewis Blood Group Antigen
1989-1999

G-CSF Effective with M-VAC Chemotherapy
Prognostic Factors Identified

1992-1999 Molecular Analysis (Rb, p53, mdm22, p16, p21, INK4A)
1995-1999 ITP Chemotherapy Improves Survival. and Post-Chemotherapy Surgery Found Beneficial
1997 New Staging for Bladder Cancer (Generated by Memorial Sloan Kettering's Department of Urology and Pathology) Adopted by AJCC/UICC
2003-2005 Defined Survival Benefit Related to the Quality of the Pelvic Lymph Node Dissection in Patients Undergoing Radical Cystectomy
Defined Refractory Carcinoma-In-Situ

Prostate Cancer

  Contributions in Treatment and Research
1950-1960 Ablative Surgery
Adrenalectomy
Exenteration for Locoregional Cancers
1970 Whitmore Staging System (AJCC)
Technique of Retropubic I125 Implantation
Natural History Defined
1974 Flutamide
Polyamine
1993 Cloning of PSMA Gene
Prostate-Specific Monoclonal Antibodies
Neoadjuvant Hormonal Therapy and Radical Prostatectomy
Three-Dimensional Conformal Radiation Therapy with Intensity Modulation
1995 Flutamide Withdrawal Syndrome
1999 Prognostic Nomograms
Nerve Grafts with Radical Prostatectomy
Quality of Life, Utility Assessment
2004-2006 Surgeon as an Independent Predictor of Outcomes

Testis Cancer

  Contributions in Treatment and Research
1960 Technique of Retroperitoneal Lymph Node Dissection
1972-7980 Cisplatin-Based Combination Chemotherapy
VAB-I through VAB-VI Protocols
Hydration for High-Dose Cisplatin Chemotherapy
Salvage Surgery Post-Chemotherapy
Adjuvant Chemotherapy
1979 Surveillance for Stage I Nonseminomatous Germ Cell Testis Tumors
1983 Risk-Adjusted Treatment Strategies
Salvage Chemotherapies
1988 Marker Gene I(12)p
1997 Staging System Incorporating Tumor Markers Defined
Mechanism of TP53 Mutations and Resistance

Renal Cancer

  Contributions in Treatment and Research
1949 Technique of Radical Nephrectomy
1975 Tumor Vaccine Developed
Monoclonal Antibodies
1979 Partial Nephrectomy in Patients with Normal Contralateral Kidney
1997 Histologic and Molecular Genetic Classification
1998 Randomized Trials of Cis-Retinoic Acid ± Interferon
1997-2000 Prognostic Factors and Nomogram
2006 Partial Nephrectomy Prevents Chronic Kidney Disease

Penile And Urethral Cancer

  Contributions in Treatment and Research
1956 Technique of Radical Groin Dissection
1983 Extended Radical Excision (Pubectomy, Emasculation)